|
|
Article: Tysabri Safety Data Good, But Skepticism Dies Hard.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Having found no new cases of progressive multifocal leukoencephalopathy in a completed safety review of Tysabri patients, Biogen Idec Inc. and Elan Corp. plc said they hope to get the multiple sclerosis drug back on the market, with regulatory paperwork to be filed in the fall.
Wall Street seemed to like it. Biogen Idec's stock (NASDAQ:BIIB) closed Tuesday at $41.24, up $2.82. Dublin, Ireland-based Elan's shares (NYSE:ELN) ended the day at $9.09, up $1.09, or 13.6 percent.
Somewhat less sanguine was Solomon Margolin, a well-known MS and drug researcher. President of Dallas-based Marnac Inc., he co-discovered and developed ...